RESUMEN
A novel spleen tyrosine kinase (SYK) P-site inhibitor, 1,4-Bis (9-O dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C-61), (but not vehicle) markedly enhanced H(2)O(2)-induced apoptosis of primary leukemia cells from each of five relapsed B-lineage acute lymphoblastic leukemia (ALL) patients, as measured by in vitro TUNEL assays. A highly radiation-resistant subclone of the murine B-lineage leukemia cell line BCL-1 was next used to investigate the in vivo radiosensitizing effects of C-61. C-61 enhanced the antileukemia potency of 7 Gy total-body irradiation (TBI) in the context of syngeneic bone marrow transplantation (BMT) at 20% of its nonobservable adverse effect level (NOAEL) that does not exhibit detectable single-agent activity against BCL-1 leukemia in vivo. Based on this preclinical proof-of-principle study, we hypothesize that the incorporation of C-61 into the pretransplant TBI regimens of patients with recurrent or high-risk B-lineage acute lymphoblastic leukemia (ALL) will help overcome the radiochemotherapy resistance of their leukemia cells and thereby improve their treatment response and survival outcome after BMT.
Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/antagonistas & inhibidores , Péptidos y Proteínas de Señalización Intracelular/química , Leucemia/patología , Leucemia/radioterapia , Ftalazinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/química , Fármacos Sensibilizantes a Radiaciones/farmacología , Animales , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Sitios de Unión/efectos de los fármacos , Línea Celular Tumoral , Femenino , Humanos , Leucemia/metabolismo , Ratones , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/efectos de la radiación , Quinasa Syk , Irradiación Corporal TotalRESUMEN
We describe the use of a parametric lognormal model to calculate and compare survival statistics in the clinical treatment of advanced/metastatic pancreatic, breast and colon cancers. The fit using the lognormal model explained greater than 90% (R(2) ranged from 0.917 to 0.998 for a total of the 51 arms from published studies) of the variation in the cumulative survival statistics of patients treated for advanced cancers. A meta-analytic Q-test was performed to test whether there were significant differences between different studies. For all three cancer types, the Q-test showed highly significant differences between the survival arms (p<0.0001 for pancreatic, breast and colon cancers). The z-values expressed the difference of the average of lognormal means relative to each study in terms of deviation expressed in standard errors. The treatments that were most effective ranked with the highest z-value: Doxorubicin plus docetaxel for pancreatic cancer (z-value = 4.1); Capecitabine plus paclitaxel for breast cancer (z-value = 3); irinotecan, fluorouracil and folinate for colon cancer (z-value = 7.4).
Asunto(s)
Metaanálisis como Asunto , Neoplasias/mortalidad , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/mortalidad , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/mortalidad , Humanos , Estimación de Kaplan-Meier , Modelos Estadísticos , Neoplasias/tratamiento farmacológico , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/mortalidad , PronósticoRESUMEN
We examined the effect of cellular metabolism of three alkyl-substituted amino acid ester phosphoramidate derivatives of stavudine in different cell lines. Marked cell-to-cell differences were found in both the rate of hydrolysis and chiral selectivity. This selectivity implies that different enzymes may be involved in the metabolism of these compounds depending on the cell type involved. Notably, both the methyl and ethyl substituted derivatives underwent hydrolysis in presence of various cell lines, whereas the tert-butyl substituted compound was resistant to hydrolysis implying that steric hindrance associated with this group along with electron density may play a key role in the hydrolysis profile of these compounds. Additionally we found this mimicked the hydrolysis profiles obtained for bacterial enzymes. Furthermore, our results suggest that the site of attack of the cellular enzymes is confined to the ester side chain of the molecule. This result is also consistent with our earlier observation using bacterial enzymes as well as using 'd' isomers.
Asunto(s)
Amidas/farmacología , Ácidos Fosfóricos/farmacología , Estavudina/farmacología , Amidas/síntesis química , Amidas/química , Animales , Sitios de Unión , Células COS , Línea Celular , Chlorocebus aethiops , Esterasas/química , Humanos , Hidrólisis/efectos de los fármacos , Células Jurkat , Lipasa/química , Ratones , Estructura Molecular , Péptido Hidrolasas/química , Ácidos Fosfóricos/síntesis química , Ácidos Fosfóricos/química , Estavudina/síntesis química , Estavudina/químicaRESUMEN
The synthesis of naphthylphosphoramidate derivatives of stavudine was achieved using a four-step procedure. The derivatives were subjected to several different enzymes including lipase, esterase, Subtilisin Carlsberg, and Carica papaya, and their hydrolysis rates were determined. Based on the rates of hydrolysis, we were able to differentiate between the chiralities at the phosphorus center of the phosphoramidate compounds. In addition, lipase was found to distinguish between both alpha and beta forms of the compounds. The superior chiral selectivity shown by lipase toward the naphthyl substituted phosphoramidate derivatives is attributed to the restrictive binding pocket of the lipase.
Asunto(s)
Amidas/química , Naftalenos/química , Ácidos Fosfóricos/química , Estavudina/síntesis química , Estavudina/metabolismo , Amidas/metabolismo , Carica/enzimología , Esterasas/química , Hidrólisis , Lipasa/química , Estructura Molecular , Naftalenos/metabolismo , Ácidos Fosfóricos/metabolismo , Serina Endopeptidasas/química , Estavudina/análogos & derivados , Estereoisomerismo , Subtilisinas/química , Factores de TiempoRESUMEN
Changing the nucleoside group of a series of phosphoramidate derivatives affects the enzyme mediated hydrolysis rate of the compounds. d4T and AZT-substituted analogs were activated by enzymes such as lipases, esterases, and proteases. On the other hand, 3dT-substituted derivatives were comparatively less prone to hydrolysis under similar experimental conditions. From the experimental results, we propose that the most preferable nucleoside group for enzyme activation is d4T rather than AZT or 3dT. Additionally, we also observed that depending on the enzymes used the chiral selectivity of the enzymes for the phosphorus center of these phosphoramidate derivatives differed, demonstrating the importance of the nucleoside structure for this class of compounds.
Asunto(s)
Amidas/química , Amidas/uso terapéutico , Fármacos Anti-VIH/química , Fármacos Anti-VIH/uso terapéutico , Ácidos Fosfóricos/química , Ácidos Fosfóricos/uso terapéutico , Zidovudina/química , Zidovudina/uso terapéutico , Animales , Línea Celular Tumoral , Didesoxinucleótidos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/uso terapéutico , Esterasas/metabolismo , Humanos , Cinética , Lipasa/metabolismo , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Péptido Hidrolasas/metabolismo , Fenol/química , Estavudina/análogos & derivados , Estavudina/química , Estavudina/metabolismo , Estavudina/farmacología , Estereoisomerismo , Relación Estructura-Actividad , Timidina Monofosfato/análogos & derivados , Timidina Monofosfato/química , Timidina Monofosfato/metabolismo , Timidina Monofosfato/farmacología , Zidovudina/análogos & derivadosRESUMEN
Several proteases are capable of hydrolyzing the aryl substituted phosphoramidate derivatives of stavudine resulting in the formation of the active metabolite, alaninyl d4T monophosphate. Subtilisin Protease A, Subtilisin Griseus, Subtilisin Carlsberg, Papaya, Bacillus were amongst the most effective proteases in hydrolyzing stavudine derivatives and specificity of their activity was confirmed using several protease inhibitors to block the hydrolysis of these phosphoramidate derivatives. We found that these proteases exhibit chiral selectivity at the phosphorus center of stavudine derivatives. Our results indicate that cellular proteases may be responsible for the activation of these phosphoramidate derivatives. In addition, we show that the enzymatic hydrolysis takes place at the carboxymethyl ester side chain of these pro-drugs and the direct attack on the phosphorus center by these enzymes does not occur. Finally, we describe a novel activation pathway hitherto unknown for the activation and viral inhibitory characteristic shown by these phosphoramidate derivatives of stavudine.
Asunto(s)
Amidas/síntesis química , Péptido Hidrolasas/metabolismo , Ácidos Fosfóricos/síntesis química , Profármacos/farmacocinética , Estavudina/análogos & derivados , Timidina Monofosfato/análogos & derivados , Amidas/química , Amidas/farmacocinética , Biotransformación , Didesoxinucleótidos , Espectroscopía de Resonancia Magnética , Ácidos Fosfóricos/química , Ácidos Fosfóricos/farmacocinética , Espectrofotometría Ultravioleta , Estavudina/síntesis química , Estavudina/metabolismo , Estavudina/farmacocinética , Estereoisomerismo , Timidina Monofosfato/metabolismoRESUMEN
The pharmacokinetics, metabolism, and toxicity of Zidampidine, an aryl phosphate derivative of AZT, 3'-azidothymidine-5'-[p-bromophenyl methoxyalaninyl phosphate] were investigated in CD-1 mice. Following iv injection, Zidampidine was rapidly converted to its metabolites Ala-AZT-MP and AZT. Zidampidine was not toxic to mice at doses up to 250mg/kg. We next examined the therapeutic effect of Zidampidine in CBA mice challenged with intracerebral injections of the Josiah strain of Lassa virus. Mice were treated either with vehicle or non-toxic doses of Zidampidine administered intraperitoneally 24h prior, 1h prior, and 24, 48, 72, and 96h after virus inoculation. The probability of survival following the Lassa challenge was significantly improved for Zidampidine-treated mice (Kaplan Meier, Log-Rank p value<0.0001). This pilot study provides the basis for future preclinical evaluation of Zidampidine and its potential as a new agent for the treatment of viral hemorrhagic fevers caused by Lassa virus.
Asunto(s)
Fiebre de Lassa/tratamiento farmacológico , Virus Lassa/efectos de los fármacos , Zidovudina/análogos & derivados , Zidovudina/farmacología , Animales , Didesoxinucleótidos , Modelos Animales de Enfermedad , Femenino , Hidrólisis , Ratones , Ratones Endogámicos ICR , Estructura Molecular , Nucleótidos de Timina , Factores de Tiempo , Zidovudina/metabolismo , Zidovudina/toxicidadRESUMEN
Mammalian proteases have not been implicated in the metabolism of any nucleoside phosphoramidate prodrug. The results presented herein provide unprecedented and conclusive experimental evidence that mammalian proteases are capable of hydrolyzing stavudine phosphoramidates. Specifically, cathepsin B and Proteinase K are able to metabolize stampidine and other phosphoramidate derivatives of stavudine. Additionally, cathepsin B exhibits chiral selectivity at the phosphorus center. The elucidation of the metabolic pathways leading to activation of stampidine may provide the basis for pharmacologic interventions aimed at modulating the metabolism and thereby improving the therapeutic window of stampidine as an anti-HIV agent.
Asunto(s)
Amidas/química , Péptido Hidrolasas/química , Ácidos Fosfóricos/química , Estavudina/análogos & derivados , Estavudina/química , Timidina Monofosfato/análogos & derivados , Amidas/metabolismo , Animales , Catepsina B/química , Bovinos , Didesoxinucleótidos , Endopeptidasa K/química , Hidrólisis , Cinética , Estructura Molecular , Ácidos Fosfóricos/metabolismo , Estavudina/metabolismo , Timidina Monofosfato/química , Timidina Monofosfato/metabolismoRESUMEN
Stampidine and other halogen substituted stavudine phosphoramidates can be activated by lipase-mediated hydrolysis. The target site for the lipase appears to be the methyl ester group of the L-alanine side chain. Accordingly, the D-amino acid substituted isomers {Rp or Sp}are resistant to lipase-mediated hydrolysis and exhibit substantially less anti-HIV activity. Molecular modeling results indicate that the L-amino acid configured isomers {Rp or Sp} are preferred in the lipase binding pocket.
Asunto(s)
Amidas/química , Lipasa/metabolismo , Ácidos Fosfóricos/química , Inhibidores de la Transcriptasa Inversa/farmacología , Estavudina/análogos & derivados , Estavudina/farmacología , Timidina Monofosfato/análogos & derivados , Timidina Monofosfato/farmacología , Amidas/metabolismo , Cromatografía Líquida de Alta Presión , Didesoxinucleótidos , Humanos , Hidrólisis , Técnicas In Vitro , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Ácidos Fosfóricos/metabolismo , Inhibidores de la Transcriptasa Inversa/química , Espectrofotometría Ultravioleta , Estavudina/química , Estavudina/metabolismo , Estereoisomerismo , Linfocitos T/efectos de los fármacos , Timidina Monofosfato/química , Timidina Monofosfato/metabolismoRESUMEN
A comparative study of aryl phosphoramidate and aryl thiophosphoramidate derivatives of 2',3'-didehydro-2',3'-dideoxythymidine (d4T) was performed. The study focused on the nature of the substituents and the influence of a thiophosphoramidate in the structure of these derivatives. The rate of alkaline hydrolysis of these two types of d4T derivatives indicated that replacement of oxygen with sulfur decreases the rate of hydrolysis by twofold. Additionally, the activation energy (E(a)) for the sulfur analogs is comparatively higher than that of the oxygen analogs. Notably, an intermediate was formed in the hydrolysis reaction of the sulfur analogs of d4T that was absent in the case of the oxygen analog, and the tentative structure of the intermediate was proposed based on LC/mass spectroscopy data. Using both HPLC and (31)P-NMR techniques, we identified the hydrolysis product of the phosphoramidate derivatives and were able to show in in vitro studies that porcine liver esterase can hydrolyze the methyl ester portion of the phosphoramidate derivatives. Aryl phosphoramidate derivatives of d4T were 1000-fold more active than the corresponding aryl thiophosphoramidate derivatives, indicating that the energy of activation of hydrolysis of these phosphoramidate derivatives plays a significant role in their biological potency.
Asunto(s)
Amidas/química , Amidas/metabolismo , Fosfatos/química , Fosfatos/metabolismo , Ácidos Fosfóricos/química , Ácidos Fosfóricos/metabolismo , Estavudina/análogos & derivados , Estavudina/metabolismo , Animales , Células Cultivadas , Humanos , Hidrólisis , Estavudina/química , PorcinosRESUMEN
This review focuses on our approach to the study of the effect of a series of phosphoramidate substituted nucleoside analogs on model systems for cancer, HIV and fertility. This approach allowed the development of compound WHI-07, an arylphosphoramidate derivative of zidavudine. This compound is a multifunctional agent showing potent activity in the above mentioned model systems. Our rational drug design provided such a powerful derivative with all the necessary characteristic of a drug candidate. Importantly, we have experimental evidence that each of the groups associated with the molecular frame of WHI-07 imparts the multifunctional ability for this agent. In addition, we have also suggested a possible biological pathway for WHI-07 including various products with their therapeutic targets that are formed during the course of its metabolism inside the cell. We also propose which individual moieties in the structure of WHI-07 are responsible for the biological activity from the formation of these metabolites. A detailed structure-activity relationship is presented in the review in connection with various structural modifications of the agent. Application of this active agent in animal models shows the potential usefulness of this agent as a drug candidate. We further plan to utilize gene-chip technology to identify new targets and modes of action using microarrays to measure expression changes in thousands of gene products. In conclusion, we have demonstrated the power of multifunctional drug design to discover drugs to combat various diseases. We believe this is the future direction of the drug discovery process.
Asunto(s)
Amidas/química , Diseño de Fármacos , Ácidos Fosfóricos/química , Timidina Monofosfato/análogos & derivados , Timidina Monofosfato/química , Zidovudina/análogos & derivados , Zidovudina/química , Amidas/farmacología , Amidas/uso terapéutico , Animales , Didesoxinucleótidos , Relación Dosis-Respuesta a Droga , Fármacos para la Fertilidad/química , Fármacos para la Fertilidad/farmacología , Fármacos para la Fertilidad/uso terapéutico , Humanos , Neoplasias/tratamiento farmacológico , Nucleósidos/química , Nucleósidos/farmacología , Nucleósidos/uso terapéutico , Ácidos Fosfóricos/farmacología , Ácidos Fosfóricos/uso terapéutico , Timidina Monofosfato/farmacología , Timidina Monofosfato/uso terapéutico , Zidovudina/farmacología , Zidovudina/uso terapéuticoRESUMEN
BTK (Bruton's tyrosine kinase) is a member of the TEC family of tyrosine kinases that plays a central but diverse modulatory role in various cellular processes. The unique role of BTK in a multitude of signaling pathways, its function as a dual regulator of apoptosis and its involvement in a number of developmental processes makes BTK a desirable target for potential anti-cancer, anti-inflammatory and anti-viral agents as well as other treatments. The biochemistry and signaling networks of BTK were well described in numerous detailed reviews written by members of our team and others before us. Therefore in this particular review we are going to concentrate on the possible practical application of previously obtained knowledge to specific diseases and disorders.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Agammaglobulinemia Tirosina Quinasa , Animales , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Humanos , Hipersensibilidad/tratamiento farmacológico , Hipersensibilidad/enzimología , Neoplasias/tratamiento farmacológico , Neoplasias/enzimología , Proteínas Tirosina Quinasas/metabolismoRESUMEN
Pokeweed antiviral protein (PAP), a 29-kDa plant-derived protein isolated from Phytolacca americana, is a broad-spectrum antiviral agent. PAP shows unique clinical potential to become the active ingredient of a non-spermicidal microbicide because of its potent in vivo anti-HIV activity, non-interference with in vivo sperm functions, and lack of cytotoxicity to genital tract epithelial cells. Over 13 weeks the subchronic and reproductive toxicity potential of an intravaginally administered gel formulation of PAP was studied in mice to support its further development as a vaginal microbicide. Female B6C3F1 and CD-1 mice in subgroups of 20, were exposed intravaginally to a gel formulation containing 0, 0.025, 0.05, or 0.1% PAP, 5 days/week for 13 consecutive weeks. On a molar basis, these concentrations are 500- to 2000-times higher than the in vitro anti-HIV IC50 value. After 13 weeks of intravaginal treatment, B6C3F1 mice were evaluated for survival, body weight gain, and absolute and relative organ weights. Blood was analyzed for hematology and clinical chemistry profiles. Microscopic examination was performed on hematoxylin and eosin-stained tissue sections from each study animal. Placebo-control and PAP-dosed female CD-1 mice were mated with untreated males in order to evaluate if PAP has any deleterious effects on reproductive performance. There were no treatment-related mortalities. Mean body weight gain was not reduced by PAP treatment during the dosing period. The hemogram and blood chemistry profiles revealed lack of systemic toxicity following daily intravaginal instillation of PAP for 13 weeks. No clinically significant changes in absolute and relative organ weights were noted in the PAP dose groups. Extensive histopathological examination of tissues showed no increase in treatment-related microscopic lesions in any of the three PAP dose groups. Repeated intravaginal exposure of CD-1 mice to increasing concentrations of PAP for 13 weeks showed no adverse effect on their subsequent reproductive capability (100% fertile), neonatal survival (>90%) or pup development. Collectively, these findings demonstrate that repetitive intravaginal administration of PAP at concentrations as high as 2000 times its in vitro anti-HIV IC50 value was not associated with local or systemic toxicity and did not adversely affect the reproductive performance of mice. PAP may be useful as an active ingredient of a safe vaginal microbicide for prevention of the sexual transmission of viruses, particularly of HIV-1.
Asunto(s)
Fármacos Anti-VIH/farmacología , Infecciones por VIH/prevención & control , VIH-1/efectos de los fármacos , Phytolacca americana , Fitoterapia , Extractos Vegetales/farmacología , Administración Intravaginal , Animales , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/toxicidad , Análisis Químico de la Sangre , Femenino , Fertilidad/efectos de los fármacos , Infecciones por VIH/transmisión , Concentración 50 Inhibidora , Masculino , Ratones , Ratones Endogámicos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/toxicidad , Enfermedades de Transmisión Sexual/prevención & control , Enfermedades de Transmisión Sexual/transmisión , Pruebas de Toxicidad , Vagina/efectos de los fármacosRESUMEN
Enzymatic hydrolysis of stampidine and other aryl phosphate derivatives of stavudine were investigated using the Candida Antarctica Type B lipase. Modeling studies and comparison of the hydrolysis rate constants revealed a chiral preference of the lipase active site for the putative S-stereoisomer. The in vitro anti-HIV activity of these compounds correlated with their susceptibility to lipase- (but not esterase-) mediated hydrolysis. We propose that stampidine undergoes rapid enzymatic hydrolysis in the presence of lipase according to the following biochemical pathway: During the first step, hydrolysis of the ester group results in the formation of carboxylic acid. Subsequent step involves an intramolecular cyclization at the phosphorous center with simultaneous elimination of the phenoxy group to form a cyclic intermediate. In the presence of water, this intermediate is converted into the active metabolite Ala-d4T-MP. We postulate that the lipase hydrolyzes the methyl ester group of the l-alanine side chain to form the cyclic intermediate in a stereoselective fashion. This hypothesis was supported by experimental data showing that chloroethyl substituted derivatives of stampidine, which possess a chloroethyl linker unit instead of a methyl ester side chain, were resistant to lipase-mediated hydrolysis, which excludes the possibility of a direct hydrolysis of stampidine at the phosphorous center. Thus, our model implies that the lipase-mediated formation of the cyclic intermediate is a key step in metabolism of stampidine and relies on the initial configuration of the stereoisomers.
Asunto(s)
Amidas/química , Lipasa/metabolismo , Ácidos Fosfóricos/química , Estavudina/análogos & derivados , Estavudina/química , Estavudina/metabolismo , Timidina Monofosfato/análogos & derivados , Timidina Monofosfato/química , Timidina Monofosfato/metabolismo , Antivirales/química , Antivirales/farmacología , Candida/enzimología , Cromatografía Líquida de Alta Presión , Didesoxinucleótidos , Esterasas/metabolismo , Hidrólisis , Concentración 50 Inhibidora , Lipasa/química , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Estructura Molecular , Conformación Proteica , EstereoisomerismoRESUMEN
Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown. Among 1880 children with ALL, 75 (4%) had losses involving chromosome 7, 16 (21%) with monosomy 7, 41 (55%) with losses of 7p (del(7p)), 16 (21%) with losses of 7q (del(7q)), and two (3%) with losses involving both arms. Patients with losses involving chromosome 7 were more likely to be > or =10 years old, National Cancer Institute (NCI) poor risk, and hypodiploid than patients lacking this abnormality. Patients with or without these abnormalities had similar early response to induction therapy. Event-free survival (EFS) and survival for patients with monosomy 7 (P<0.0001 and P=0.0007, respectively) or del(7p) (P<0.0001 and P=0.0001, respectively), but not of patients with del(7q), were significantly worse than those of patients lacking these abnormalities. The poorer EFS was maintained after adjustment for a Philadelphia (Ph) chromosome, NCI risk status, ploidy, or an abnormal 9p. However, the impact on survival was not maintained for monosomy 7 after adjustment for a Ph. These results indicate that the critical region of loss of chromosome 7 in pediatric ALL may be on the p-arm.
Asunto(s)
Deleción Cromosómica , Cromosomas Humanos Par 7 , Monosomía , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Niño , Preescolar , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , PronósticoRESUMEN
Clonal genetic aberrations in tumour cells provide critical information for the development of new diagnostic and therapeutic strategies for patients. In paediatric T-cell acute lymphoblastic leukaemia (T-ALL) chromosomal translocations are present in 30-35% of cases. HOX11 and the closely related HOX11L2 genes play a key role in T-ALL. HOX11 is aberrantly activated by either of the two chromosomal translocations, t(7;10) and t(10;14). In this study, HOX11 expression levels were measured by real-time quantitative reverse-transcriptase polymerase chain reaction. We show that leukaemic blasts from 15/76 (19.7%) paediatric T-ALL patients expressed the HOX11 gene at high level and 22/76 (28.9%) at low level, yet the reported frequency for chromosomal rearrangement of 10q24 is 4-7%. Direct cytogenetic analysis revealed that only 2/16 specimens that showed HOX11 expression exhibited abnor-malities at 10q24. These results confirm and extend our previously published findings, and implicate mechanisms other than gross chromosomal translocations for the deregulation of HOX11. Analysis of clinical outcome for the whole study group showed a trend for better outcome for patients with leukaemic blasts expressing HOX11 at high level. A statistically significant difference in clinical outcome was found in a subgroup of 20 patients treated for high-risk disease on CCG-1901 from the Children's Cancer Group, where HOX11 expression in leukaemic blasts conferred a prognostic advantage (P=0.01).
Asunto(s)
Aberraciones Cromosómicas , Cromosomas Humanos Par 10/genética , Proteínas de Homeodominio/genética , Leucemia-Linfoma de Células T del Adulto/genética , Proteínas Oncogénicas/genética , Translocación Genética/genética , Médula Ósea , Linaje de la Célula , Niño , Preescolar , Cromosomas Humanos Par 14/genética , Cromosomas Humanos Par 7/genética , Análisis Citogenético , Cartilla de ADN/química , Femenino , Expresión Génica , Proteínas de Homeodominio/metabolismo , Humanos , Lactante , Masculino , Proteínas Oncogénicas/metabolismo , Ploidias , Reacción en Cadena de la Polimerasa , Proteínas Proto-Oncogénicas , ARN Mensajero/genética , Tasa de Supervivencia , Células Tumorales CultivadasRESUMEN
Mast cell derived leukotrienes (LT's) play a vital role in pathophysiology of allergy and asthma. We synthesized various analogues of indolyl, naphthyl and phenylethyl substituted halopyridyl, thiazolyl and benzothiazolyl thioureas and examined their in vitro effects on the high affinity IgE receptor/Fc epsilon RI-mediated mast cell leukotriene release. Of the 22 naphthylethyl thiourea compounds tested, there were 7 active compounds and N-[1-(1-naphthyl)ethyl]-N'-[2-(ethyl-4-acetylthiazolyl)]thiourea (17 and 16) (IC(50)=0.002 microM) and N-[1-(1R)-naphthylethyl]-N'-[2-(5-methylpyridyl)]thiourea (compound 5) (IC(50)=0.005 microM) were identified as the lead compounds. Among the 11 indolylethyl thiourea compounds tested, there were seven active compounds and the halopyridyl compounds N-[2-(3-indolylethyl)]-N'-[2-(5-chloropyridyl)]thiourea (24) and N-[2-(3-indolylethyl)]-N'-[2-(5-bromopyridyl)]thiourea (25) were the most active agents and inhibited the LTC(4) release with low micromolar IC(50) values of 4.9 and 6.1 microM, respectively. The hydroxylphenyl substituted compounds N-[2-(4-hydroxyphenyl)ethyl]-N'-[2-(5-chloropyridyl)]thiourea (37; IC(50)=12.6 microM), N-[2-(4-hydroxyphenyl)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (50; IC(50)=16.8 microM) and N-[2-(4-hydroxyphenyl)ethyl]-N'-[2-(pyridyl)]thiourea (35; IC(50)=8.5 microM) were the most active pyridyl thiourea agents. Notably, the introduction of electron withdrawing or donating groups had a marked impact on the biological activity of these thiourea derivatives and the Hammett sigma values of their substituents were identified as predictors of their potency. In contrast, experimentally determined partition coefficient values did not correlate with the biological activity of the thiourea compounds which demonstrates that their liphophilicity is not an important factor controlling their mast cell inhibitory effects. These results establish the substituted halopyridyl, indolyl and naphthyl thiourea compounds as a new chemical class of anti-allergic agents inhibiting IgE receptor/Fc epsilon RI-mediated mast cell LTC(4) release. Further lead optimization efforts may provide the basis for new and effective treatment as well as prevention programs for allergic asthma in clinical settings.
Asunto(s)
Antialérgicos/síntesis química , Antialérgicos/farmacología , Compuestos Heterocíclicos/síntesis química , Compuestos Heterocíclicos/farmacología , Leucotrienos/metabolismo , Mastocitos/metabolismo , Receptores de IgE/antagonistas & inhibidores , Tiourea/síntesis química , Tiourea/farmacología , Animales , Células Cultivadas , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Leucotrieno C4/metabolismo , Espectroscopía de Resonancia Magnética , Mastocitos/efectos de los fármacos , Rotación Óptica , Ratas , Solubilidad , Relación Estructura-ActividadRESUMEN
An efficient synthesis of carbamate analogues of the NRTI compound stavudine, has been achieved in five steps starting from commercially available thymidine. The synthesis involves conversion of thymidine into stavudine followed by condensation with carbaimidazole derivative obtained from various aromatic and heterocyclic amines in dimethylformamide solvent. The analogues thus obtained were further purified by crystallization to furnish analytically pure products. Examination of biological activity of these carbamate derivatives of stavudine showed that they inhibited HIV replication only at micro-molar concentrations.
Asunto(s)
Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/farmacología , Carbamatos/síntesis química , Carbamatos/farmacología , VIH-1/efectos de los fármacos , Estavudina/análogos & derivados , Estavudina/farmacología , Fármacos Anti-VIH/química , Carbamatos/química , Cromatografía Líquida de Alta Presión , Estabilidad de Medicamentos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Estructura Molecular , Estavudina/síntesis química , Estavudina/químicaRESUMEN
We prospectively examined the frequency of the t(12;21)TEL-AML1 fusion in 504 children with newly diagnosed standard risk ALL using RT-PCR assays. Cells from 95 patients (18.8%) were TEL-AML1+. There was a significantly higher frequency of pseudodiploidy among the TEL-AML1+ cases (39.4% versus 14.1%, P = 0.001), primarily because structural abnormalities involving 12p and del(6q) occurred more frequently in the TEL-AML1+ group. TEL-AML1+ ALL was more sensitive to the induction chemotherapy than TEL-AML1- ALL. The percentage of "rapid early responders", i.e., patients who achieved an M1 (< 5% blasts) or M2 (5-25% blasts) marrow status on day 7 of induction chemotherapy, was significantly higher among TEL-AML1+ cases. The quality of remission of RT-PCR positive cases was excellent, as evidenced by the very low to absent MRD burden of their end-of-induction bone marrow specimens. TEL-AML1+ patients also had an excellent early EFS outcome. The probability of EFS at 30 months from study entry were 98.9 +/- 1.0% for the TEL-AML1+ group and 92.1 +/- 1.5% for the TEL-AML1- group (P = 0.0001). This prospective study significantly expands the knowledge gained from previous studies regarding the prognostic significance of t(12;21)TEL-AML1 fusion in pediatric ALL.
Asunto(s)
Proteínas de Fusión Oncogénica/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Médula Ósea/efectos de los fármacos , Niño , Subunidad alfa 2 del Factor de Unión al Sitio Principal , Análisis Citogenético , Supervivencia sin Enfermedad , Humanos , Neoplasia Residual , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Estudios Prospectivos , ARN Mensajero/análisis , ARN Mensajero/metabolismo , Inducción de Remisión , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de RiesgoRESUMEN
The bioavailability and pharmacokinetic characteristics of etoposide were studied in 12 relapsed B-lineage acute lymphoblastic leukemia (ALL) patients after both intravenous (i.v.) infusion and oral administration. Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2). The AUC ranged from 2234.9 to 5427.0 microM.min) (mean +/- SD = 3827.8 +/- 1069.5 microM.min) and Vc ranged from 2026.9 to 13,505.2 ml/m2 (mean +/- SD = 6825.4 +/- 3278.5 ml/m2). The maximum plasma etoposide levels ranged from 6.0 to 28.4 microM (mean +/- SD = 13.6 +/- 6.3 microM). The bioavailability of oral etoposide was determined by comparing the AUC following i.v. infusion to the AUC following oral administration in the same patient. The overall bioavailability (mean +/- SD) was 60.6 +/- 22.4% (ranged from 17.6% to 91.2%). The elimination half-life following oral administration (mean +/- SD) was 209.8 +/- 196.3 min (ranged from 51.0 to 794.2 min). The time required to reach the maximum plasma etoposide concentration was 145.4 +/- 118.7 min (ranged from 23.7 to 396.9 min). To our knowledge, this is the first report concerning the bioavailability of etoposide in pediatric leukemia patients. All of the other pharmacokinetic properties of etoposide in pediatric B-lineage ALL leukemia patients reported here were similar to those described previously.